1. Repositório Institucional da UFMG
  2. Publicações Científicas e Culturais
  3. Artigo de Periódico
Use este identificador para citar o ir al link de este elemento: http://hdl.handle.net/1843/81438
Registro completo de metadatos
Campo DCValorIdioma
dc.creatorAna Thereza Chaves Lagespt_BR
dc.creatorAna Laura Grossi de Oliveirapt_BR
dc.creatorNathalia Sernizon Guimarãespt_BR
dc.creatorIsabela Cristina Magalhãespt_BR
dc.creatorCristiane Alves da Silva Menezespt_BR
dc.creatorManoel Otávio da Costa Rochapt_BR
dc.date.accessioned2025-04-10T13:32:51Z-
dc.date.available2025-04-10T13:32:51Z-
dc.date.issued2022-
dc.citation.volume64pt_BR
dc.citation.spage1pt_BR
dc.citation.epage9pt_BR
dc.identifier.doihttp://doi.org/10.1590/S1678-9946202264045pt_BR
dc.identifier.issn1678-9946pt_BR
dc.identifier.urihttp://hdl.handle.net/1843/81438-
dc.description.resumoChronic Chagas Cardiomyopathy (CCC) is the most prevalent type of myocarditis and the main clinical form of the Chagas disease, which has peculiarities such as focal inflammation, structural derangement, hypertrophy, dilation, and intense reparative fibrosis. Many cellular compounds contribute to CCC development. Galectin-3 is a partaker in inflammation and contributes to myocardial fibrosis formation. Some studies showed the connection between Galectin-3 and fibrosis in Chagas disease but are still inconclusive on the guidance for the early implementation of pharmacological therapy. This systematic review evaluated Galectin-3 as a biomarker for fibrosis intensity in CCC. Two independent reviewers have searched five databases (PubMed, EMBASE, Cochrane Library, Scopus, and Lilacs), using the following search terms: galectin-3, biomarkers, fibrosis, Chagas cardiomyopathy, and Chagas disease. Overall, seven studies met the inclusion criteria and made up this review. There were four trials conducted through animal model experiments and three trials with humans. Experimental data in mice indicate an association between Galectin-3 expression and fibrosis in CCC (75% of studies). Data from human studies showed no direct connection between myocardial fibrosis and Galectin-3 expression (80% of studies). Thus, human findings do not provide significant evidence indicating that Galectin-3 is related to fibrosis formation in Chagas disease. Based on the analyzed studies, it is suggested that Galectin-3 might not be a good fibrosis marker in CCC.pt_BR
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Geraispt_BR
dc.format.mimetypepdfpt_BR
dc.languageengpt_BR
dc.publisherUniversidade Federal de Minas Geraispt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentFAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICASpt_BR
dc.publisher.departmentMED - DEPARTAMENTO DE CLÍNICA MÉDICApt_BR
dc.publisher.initialsUFMGpt_BR
dc.relation.ispartofInstituto de medicina tropical de São Paulopt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectGalectin-3pt_BR
dc.subjectChronic Chagas Cardiomyopathypt_BR
dc.subjectFibrosispt_BR
dc.subject.otherGalectina 3pt_BR
dc.subject.otherCardiomiopatia chagásicapt_BR
dc.subject.otherDoença de Chagaspt_BR
dc.subject.otherFibrosept_BR
dc.titleGalectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic reviewpt_BR
dc.typeArtigo de Periódicopt_BR
Aparece en las colecciones:Artigo de Periódico

archivos asociados a este elemento:
archivo Descripción TamañoFormato 
Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy a systematic review.pdf258.31 kBAdobe PDFVisualizar/Abrir
Mostrar registro simple del elemento Visualizar estadísticas


Los elementos en el repositorio están protegidos por copyright, con todos los derechos reservados, salvo cuando es indicado lo contrario.